Dr Agarwals Health Care Ltd · AGARWALEYE
—
—
—
—
—
₹333 Cr
₹349 Cr
₹403 Cr
₹417 Cr
₹431 Cr
₹460 Cr
₹487 Cr
₹499 Cr
₹530 Cr
₹564 Cr
₹614 Cr
20-quarter listed-company comparison
Hospitals/Medical Services Stocks in India
Hospitals/Medical Services: Dr Agarwals Health Care Ltd owns the largest revenue base; Gujarat Kidney & Super Speciality Ltd has the fastest current growth.
01 · the index people search for
Nifty Hospitals/Medical Services Index — Constituents & Performance
The Hospitals/Medical Services companies below are the listed Indian Hospitals/Medical Services universe this page tracks — the same constituent set people search for as the Nifty Hospitals/Medical Services index. Every figure is equal-weighted across those companies, so one large constituent cannot set the reading. Each number carries its own as-of date.
02 · the sector itself · before any single company
How has Hospitals/Medical Services moved against NIFTY 500?
The line below covers up to 2.9 years. Over the most recent two of them this sector is 242% ahead of NIFTY 500. Earnings across its companies fell 94% on average over the last four reported quarters. It has been ahead of NIFTY 500 on a rolling three-month view for 58 weeks running.
LEADER · ahead 58w·Price up, without the fundamentals confirming4 of 6 companies ahead of NIFTY 500 by 5% or more over three months
RS ↑58w · 5/5 >200d (+1) · 4/6 lead (−1) · EPS —
Hospitals/Medical Services, equal-weighted, based at 200
NIFTY 500, same base, same start
trailing 12-month earnings per share rising
falling
Both lines start at 200 in the same week, so the distance between them is the whole story: the sector line is an equal-weighted index of its 6 companies. The bars underneath are trailing 12-month earnings per share, one bar per reported quarter, each member rebased to 100 at the start and the sector taking the median — so a price line pulling away from flat bars is a re-rating, not earnings. A bar turns red when that figure is lower than the quarter before. Rules are fixed and applied identically everywhere on this site: ahead by 5% or more over three months, or behind by 20% or more over a year while earnings grew 20% or more. Hover any point to read both values and the gap. This is a description of what the numbers did, not advice.
03 · sector relative strength, before individual stocks
Is Hospitals/Medical Services outperforming NIFTY 500?
Hospitals/Medical Services has outperformed NIFTY 500 by 146.2% over the last 52 weeks. Over 13 weeks the gap is a lead of 13%. 2 of 2 covered companies currently beat NIFTY on Mansfield relative strength, so leadership inside the sector is selective. Unihealth Hospitals Ltd is the strongest against the sector itself at +30.2%. Readings are as of 2026-08-09.
+13.0%Sector vs NIFTY 500 · 13 weeks
+146.2%Sector vs NIFTY 500 · 52 weeks
2/2Stocks leading NIFTY 500
1/2Stocks leading sector
Sector metric: 26.1 as of 2026-08-09 · NARROWING · rising.
The central tension: the companies with the most scale are not necessarily the companies creating the most change.
Start with scale. Then earnings trajectory. Then business quality. Only after those three agree should price leadership carry much weight.
Bottom line
Hospitals/Medical Services has outperformed NIFTY 500 by 146.2% over 52 weeks and 13% over 13 weeks. 2 of 2 covered companies beat NIFTY on Mansfield relative strength, while 1 of 2 beat the sector itself. Dr Agarwals Health Care Ltd leads with revenue of ₹2,207 crore, based on 5 of 7 comparable companies through Jun 2026.
Companies
7
complete canonical membership
Combined market value
₹38.9K Cr
Dr Agarwals Health Care Ltd
Revenue growing
3/3
positive TTM year-on-year growth
Beating NIFTY 500
2/2
positive Mansfield relative strength
Comparing 5 of 7
04 · research priority, made explicit
Best Hospitals/Medical Services Stocks in India (Aug 2026), Ranked by Data
4-Factor Sector Score
An additive sector-relative research score. The four displayed point contributions always equal the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or stale evidence is absorbed inside the affected factor, never applied as a hidden adjustment.
Growth & earnings · 35%Capital efficiency · 25%Valuation · 20%Relative strength · 20%
Unihealth Hospitals Ltd has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 55.8% evidence confidence.
How this score is built, and what the marks mean
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Top 10 Hospitals/Medical Services Stocks in India
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Unihealth Hospitals LtdUNIHEALTH | 69.3/100Thin evidence · provisional56% evidence | LEADER | 19.0/35 Revenue — · PAT — · OPM change -4 pp 26% evidence | 19.8/25 ROCE 24.5% · OPM 34% 95% evidence | 10.5/20 P/E 41.9× · PEG — 15% evidence | 20.0/20 RS sector 30.2% · RS bench 77.7% · 1Y 321%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19 + 19.8 + 10.5 + 20 = 69.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 2Dr Agarwals Health Care LtdAGARWALEYE | 55.1/100Mixed-positive evidence69% evidence | BREAKING OUT | 29.1/35 Revenue 22.9% · PAT 42.3% · OPM change 2 pp 95% evidence | 9.6/25 ROCE 11.1% · OPM 28% 76% evidence | 8.5/20 P/E 109× · PEG — 15% evidence | 7.9/20 RS sector -38.8% · RS bench 4.9% · 1Y 14%7 of 11 weeks ahead 70% evidence |
| Exact sum: 29.1 + 9.6 + 8.5 + 7.9 = 55.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Nephrocare Health Services LtdNEPHROPLUS | 53.5/100Thin evidence · provisional55% evidence | FADING | 19.9/35 Revenue — · PAT — · OPM change 0 pp 48% evidence | 9.6/25 ROCE 15.3% · OPM 21% 100% evidence | 14.0/20 P/E 82.3× · PEG 0.04 65% evidence | 10.0/20 RS sector — · RS bench — · 1Y —10 of 12 weeks ahead 0% evidence |
| Exact sum: 19.9 + 9.6 + 14 + 10 = 53.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 4Gujarat Kidney & Super Speciality LtdGKSL | 49.3/100Mixed-negative evidence60% evidence | ASLEEP | 18.2/35 Revenue 100% · PAT 36.7% · OPM change -32.1 pp 95% evidence | 11.6/25 ROCE 14.5% · OPM 24.4% 95% evidence | 9.5/20 P/E 68× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —9 of 12 weeks ahead 0% evidence |
| Exact sum: 18.2 + 11.6 + 9.5 + 10 = 49.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Gaudium IVF and Women Health LtdGAUDIUMIVF | 48.7/100Mixed-negative evidence60% evidence | BREAKING OUT | 13.1/35 Revenue 16.3% · PAT 10.6% · OPM change -16.5 pp 95% evidence | 14.6/25 ROCE 29.3% · OPM 12.5% 95% evidence | 11.0/20 P/E 38.8× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —6 of 6 weeks ahead 0% evidence |
| Exact sum: 13.1 + 14.6 + 11 + 10 = 48.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6KRM Ayurveda LtdKRMAYURVED | 59.0/100Thin evidence · provisional38% evidence | TURNING | 18.5/35 Revenue — · PAT — · OPM change 12 pp 32% evidence | 19.0/25 ROCE 35.3% · OPM 37.2% 95% evidence | 11.5/20 P/E 23.9× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —11 of 12 weeks ahead 0% evidence |
| Exact sum: 18.5 + 19 + 11.5 + 10 = 59 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 7Park Medi World LtdPARKHOSPS | 52.9/100Thin evidence · provisional38% evidence | BREAKING OUT | 17.6/35 Revenue — · PAT — · OPM change 0 pp 45% evidence | 15.3/25 ROCE 19.3% · OPM 26% 76% evidence | 10.0/20 P/E 43.8× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —12 of 12 weeks ahead 0% evidence |
| Exact sum: 17.6 + 15.3 + 10 + 10 = 52.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
05 · what price has already done
Market action
Unihealth Hospitals Ltd has the strongest one-year price move in Hospitals/Medical Services at +321%. It also leads on Mansfield relative strength against NIFTY at +77.7%. 2 of 2 covered companies are above zero on that measure. Every line covers 313 weekly closes through 2026-08-14.
Price and relative strength
Every company, the sector's own index and NIFTY 500 all start level on the left edge of the window, so only the distance between the lines counts — the highest line has risen the most since then, and the chart at the top of this page is drawn the same way. It opens on one year; the buttons beside it stretch that to three or five.
How far ahead of or behind NIFTY 500 each company has been running, measured against its own recent average of that comparison, so the flat line at zero IS NIFTY 500: above it the company is beating the market, below it the market is beating the company. It opens on one year.
The same measure taken against Hospitals/Medical Services itself instead of the whole market, so the flat line at zero is the sector: above it the company is beating its own peers, which is the sharper test of the two. It opens on one year.
06 · the story behind the numbers
Hospitals/Medical Services — the story behind the numbers
This is the written read behind the Hospitals/Medical Services figures above — what is actually happening in the sector, in words, with the evidence each claim rests on. It is dated 28 Jul 2026. 3 themes are live here.
The verdict is Cautious. While growth metrics are high, regulatory penalties and lack of guidance introduce uncertainty. The operating leverage inflection depends on occupancy improving to 70%+.
The Hospitals/Medical Services sector analysis for the week ending 2026-07-19 centers on Gujarat Kidney & Super Speciality Ltd (GKSL). The constituent reported Q4 FY26 total income of ₹31.29 crore, marking a 218.3% YoY increase from ₹9.83 crore in Q4FY25. Profit after tax surged 259.7% YoY to ₹4.82 crore.
How old this read is: This read comes from our Hospitals/Medical Services sector brief dated 28 Jul 2026, so the words here and the numbers above them cover the same few weeks.
What is live in this sector right now
| Live theme | Severity | Evidence on file |
|---|---|---|
| Company paid ₹6,60,800 penalty to NSE and BSE for failing to submit quarterly financial results within prescribed timelines under Regulation 33 of SEBI LODR 2015, with additional…Named for GKSL | medium | “Company paid ₹6,60,800 penalty to NSE and BSE for failing to submit quarterly financial results within prescribed timelines under Regulation 33 of SEBI LODR 2015, with additional ₹20,000 fine for board meeting…” Company stated no additional financial impact expected from regulatory action and penalty settlement closes the matter with both exchanges. |
| Company faces heavy reliance on key doctors creating attrition risk, with revenue concentrated in IPD (73%) and Gujarat region limiting diversification.Named for GKSL | medium | “Company faces heavy reliance on key doctors creating attrition risk, with revenue concentrated in IPD (73%) and Gujarat region limiting diversification.” |
| Multiple regulatory violations cited including delay in furnishing prior intimation about Board of Directors meeting, contravening listing requirements.Named for GKSL | low | “Multiple regulatory violations cited including delay in furnishing prior intimation about Board of Directors meeting, contravening listing requirements.” Company stated levy of fines has no impact on financial, operational, or any other activities. |
Sources: our Hospitals/Medical Services sector brief, 28 Jul 2026 · company earnings-call transcripts.
07 · compare level, then change
Revenue Scale & Growth Durability
Dr Agarwals Health Care Ltd has the highest Revenue among the 7 Hospitals/Medical Services companies compared here, at ₹2,207 crore. Park Medi World Ltd is next at ₹1,756 crore. Gujarat Kidney & Super Speciality Ltd has the highest Revenue growth at the 100% top of the scoring scale, so level and change sit with different companies.
What the numbers say: Dr Agarwals Health Care Ltd is the scale leader at ₹2,207 crore, 25.7% ahead of Park Medi World Ltd. Gujarat Kidney & Super Speciality Ltd's growth is stored at the ≥100% scoring cap; the uncapped TTM change is 118.5% from a ₹101 crore base, with 8 reported observations in the 20-quarter window. Treat the growth leader as an acceleration candidate, not as equally proven scale.
LeaderDr Agarwals Health Care Ltd · ₹2,207 crore
Gap25.7% versus #2 · Park Medi World Ltd
Persistence7/7 recent comparable periods
Coverage5/7 companies · 52 observations
Investor read: Dr Agarwals Health Care Ltd is the scale benchmark; Gujarat Kidney & Super Speciality Ltd is the acceleration watch. Promote the challenger only if growth persists and converts into margin and returns.
This conclusion weakens if: Dr Agarwals Health Care Ltd's growth falls below Gujarat Kidney & Super Speciality Ltd's for two consecutive comparable reports while operating margin also compresses.
Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.
Revenuelargest
4Gaudium IVF and Women Health Ltd GAUDIUMIVF⚠ unverified₹106 Cr
Revenue growthfastest growers
3Gaudium IVF and Women Health Ltd GAUDIUMIVF⚠ unverified16%
Revenue · company comparison
5/7 level · 3/7 change
On every company-comparison chart on this page: solid lines show level, dotted lines show change when “Both” is selected, and a missing report breaks the line rather than being invented.
All-company data · latest reported quarter
In every all-company table on this page, each figure is the company’s latest single reported quarter. The rankings above them use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | Revenue | Revenue growth | Reported |
|---|---|---|---|
| Dr Agarwals Health Care Ltd AGARWALEYE | ₹614 Cr | 26% | Jun 2026 |
| Park Medi World Ltd PARKHOSPS | ₹476 Cr | 19% | Jun 2026 |
| Nephrocare Health Services Ltd NEPHROPLUS | ₹282 Cr | 24% | Jun 2026 |
| Unihealth Hospitals Ltd UNIHEALTH⚠ unverified | ₹65 Cr | 16% | Mar 2026 |
| Gujarat Kidney & Super Speciality Ltd GKSL⚠ unverified | ₹34 Cr | 125% | Jun 2026 |
| KRM Ayurveda Ltd KRMAYURVED | ₹32 Cr | 31% | Jun 2026 |
| Gaudium IVF and Women Health Ltd GAUDIUMIVF⚠ unverified | ₹19 Cr | 9.1% | Jun 2026 |
Full 16-quarter history · every available company
Revenue · reported quarter history
Gaudium IVF and Women Health Ltd · GAUDIUMIVF⚠ unverified
—
—
—
—
—
—
—
—
₹32 Cr
₹14 Cr
₹27 Cr
₹18 Cr
₹32 Cr
₹25 Cr
₹30 Cr
₹19 Cr
Gujarat Kidney & Super Speciality Ltd · GKSL⚠ unverified
—
—
—
—
—
—
—
—
₹9 Cr
₹12 Cr
₹10 Cr
₹15 Cr
₹13 Cr
₹23 Cr
₹31 Cr
₹34 Cr
KRM Ayurveda Ltd · KRMAYURVED
—
—
—
—
—
—
—
—
—
—
₹41 Cr
₹25 Cr
₹48 Cr
—
₹32 Cr
₹32 Cr
Nephrocare Health Services Ltd · NEPHROPLUS
—
—
—
—
—
—
—
—
—
₹197 Cr
₹219 Cr
₹228 Cr
₹246 Cr
₹260 Cr
₹266 Cr
₹282 Cr
Park Medi World Ltd · PARKHOSPS
—
—
—
—
—
—
—
—
—
₹348 Cr
₹354 Cr
₹399 Cr
₹410 Cr
₹410 Cr
₹460 Cr
₹476 Cr
Unihealth Hospitals Ltd · UNIHEALTH⚠ unverified
—
—
—
—
₹22 Cr
—
₹27 Cr
—
₹43 Cr
—
₹56 Cr
—
₹67 Cr
—
₹65 Cr
—
Revenue growth · reported quarter history
Dr Agarwals Health Care Ltd · AGARWALEYE
—
—
—
—
—
—
—
—
—
29%
32%
21%
20%
23%
23%
26%
Gaudium IVF and Women Health Ltd · GAUDIUMIVF⚠ unverified
—
—
—
—
—
—
—
—
—
—
—
—
-0.8%
70%
13%
9.1%
Gujarat Kidney & Super Speciality Ltd · GKSL⚠ unverified
—
—
—
—
—
—
—
—
—
—
—
—
37%
97%
213%
125%
KRM Ayurveda Ltd · KRMAYURVED
—
—
—
—
—
—
—
—
—
—
—
—
—
—
-21%
31%
Nephrocare Health Services Ltd · NEPHROPLUS
—
—
—
—
—
—
—
—
—
—
—
—
—
32%
21%
24%
Park Medi World Ltd · PARKHOSPS
—
—
—
—
—
—
—
—
—
—
—
—
—
18%
30%
19%
Unihealth Hospitals Ltd · UNIHEALTH⚠ unverified
—
—
—
—
—
—
—
—
95%
—
107%
—
56%
—
16%
—
08 · compare level, then change
Operating Economics & Margin Trend
KRM Ayurveda Ltd has the highest OPM among the 7 Hospitals/Medical Services companies compared here, at 37.2%. Unihealth Hospitals Ltd is next at 34%. The same company also holds the highest Margin change, at +12 percentage points. 7 of 7 companies report a comparable reading, the latest through Jun 2026.
What the numbers say: KRM Ayurveda Ltd leads both opm at 37.2% and margin change at +12 percentage points.
LeaderKRM Ayurveda Ltd · 37.2%
Gap9.4% versus #2 · Unihealth Hospitals Ltd
Persistence2/2 recent comparable periods
Coverage7/7 companies · 54 observations
Investor read: KRM Ayurveda Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current margin change signal.
Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.
OPMhighest
1KRM Ayurveda Ltd KRMAYURVED37%
Margin changefastest expanders
1KRM Ayurveda Ltd KRMAYURVED+12.0 pp
Operating margin · company comparison
7/7 level · 7/7 change
All-company data · latest reported quarter
| Company | OPM | Margin change | Reported |
|---|---|---|---|
| KRM Ayurveda Ltd KRMAYURVED | 37% | +12.0 pp | Jun 2026 |
| Unihealth Hospitals Ltd UNIHEALTH⚠ unverified | 34% | −4.0 pp | Mar 2026 |
| Dr Agarwals Health Care Ltd AGARWALEYE | 28% | +2.0 pp | Jun 2026 |
| Park Medi World Ltd PARKHOSPS | 26% | 0.0 pp | Jun 2026 |
| Gujarat Kidney & Super Speciality Ltd GKSL⚠ unverified | 24% | −32.1 pp | Jun 2026 |
| Nephrocare Health Services Ltd NEPHROPLUS | 21% | 0.0 pp | Jun 2026 |
| Gaudium IVF and Women Health Ltd GAUDIUMIVF⚠ unverified | 13% | −16.5 pp | Jun 2026 |
Full 16-quarter history · every available company
OPM · reported quarter history
Dr Agarwals Health Care Ltd · AGARWALEYE
—
—
—
—
26%
27%
31%
26%
26%
27%
28%
26%
27%
27%
29%
28%
Gaudium IVF and Women Health Ltd · GAUDIUMIVF⚠ unverified
—
—
—
—
—
—
—
—
40%
39%
32%
29%
43%
27%
40%
13%
Gujarat Kidney & Super Speciality Ltd · GKSL⚠ unverified
—
—
—
—
—
—
—
—
52%
39%
27%
56%
40%
30%
21%
24%
KRM Ayurveda Ltd · KRMAYURVED
—
—
—
—
—
—
—
—
—
—
21%
25%
27%
—
34%
37%
Nephrocare Health Services Ltd · NEPHROPLUS
—
—
—
—
—
—
—
—
—
22%
23%
21%
26%
23%
19%
21%
Park Medi World Ltd · PARKHOSPS
—
—
—
—
—
—
—
—
27%
24%
25%
26%
27%
24%
28%
26%
Unihealth Hospitals Ltd · UNIHEALTH⚠ unverified
—
—
—
—
32%
—
39%
—
35%
—
38%
—
48%
—
34%
—
Margin change · reported quarter history
Dr Agarwals Health Care Ltd · AGARWALEYE
—
—
—
—
—
—
—
—
+0.5 pp
0.0 pp
−3.0 pp
0.0 pp
+1.0 pp
0.0 pp
+1.0 pp
+2.0 pp
Gaudium IVF and Women Health Ltd · GAUDIUMIVF⚠ unverified
—
—
—
—
—
—
—
—
—
—
—
—
+3.4 pp
−12.5 pp
+7.7 pp
−16.5 pp
Gujarat Kidney & Super Speciality Ltd · GKSL⚠ unverified
—
—
—
—
—
—
—
—
—
—
—
—
−12.1 pp
−9.3 pp
−6.1 pp
−32.1 pp
KRM Ayurveda Ltd · KRMAYURVED
—
—
—
—
—
—
—
—
—
—
—
—
—
—
+13.1 pp
+12.0 pp
Nephrocare Health Services Ltd · NEPHROPLUS
—
—
—
—
—
—
—
—
—
—
—
—
—
+1.0 pp
−4.0 pp
0.0 pp
Park Medi World Ltd · PARKHOSPS
—
—
—
—
—
—
—
—
—
—
—
—
−0.4 pp
0.0 pp
+3.0 pp
0.0 pp
Unihealth Hospitals Ltd · UNIHEALTH⚠ unverified
—
—
—
—
—
—
—
—
+3.0 pp
—
−1.0 pp
—
+13.0 pp
—
−4.0 pp
—
09 · compare level, then change
Profit Scale & Acceleration
Park Medi World Ltd has the highest Net profit among the 7 Hospitals/Medical Services companies compared here, at ₹298 crore. Dr Agarwals Health Care Ltd is next at ₹185 crore. Dr Agarwals Health Care Ltd has the highest Profit growth at 42.3%, so level and change sit with different companies.
What the numbers say: Park Medi World Ltd leads with ₹298 crore of TTM profit, 61.1% above Dr Agarwals Health Care Ltd. Dr Agarwals Health Care Ltd shows 42.3% growth from a ₹185 crore profit base. Compare the size of the base and persistence before ranking acceleration above profit scale.
LeaderPark Medi World Ltd · ₹298 crore
Gap61.1% versus #2 · Dr Agarwals Health Care Ltd
Persistence3/3 recent comparable periods
Coverage5/7 companies · 52 observations
Investor read: Park Medi World Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.
Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.
Net profitlargest
4Gaudium IVF and Women Health Ltd GAUDIUMIVF⚠ unverified₹23 Cr
Profit growthfastest growers
3Gaudium IVF and Women Health Ltd GAUDIUMIVF⚠ unverified11%
Net profit · company comparison
5/7 level · 3/7 change
All-company data · latest reported quarter
| Company | Net profit | Profit growth | Reported |
|---|---|---|---|
| Park Medi World Ltd PARKHOSPS | ₹89 Cr | 35% | Jun 2026 |
| Dr Agarwals Health Care Ltd AGARWALEYE | ₹55 Cr | 45% | Jun 2026 |
| Nephrocare Health Services Ltd NEPHROPLUS | ₹32 Cr | 33% | Jun 2026 |
| Unihealth Hospitals Ltd UNIHEALTH⚠ unverified | ₹17 Cr | -5.6% | Mar 2026 |
| KRM Ayurveda Ltd KRMAYURVED | ₹9 Cr | 124% | Jun 2026 |
| Gujarat Kidney & Super Speciality Ltd GKSL⚠ unverified | ₹5 Cr | -1.5% | Jun 2026 |
| Gaudium IVF and Women Health Ltd GAUDIUMIVF⚠ unverified | ₹2 Cr | -42% | Jun 2026 |
Full 16-quarter history · every available company
Net profit · reported quarter history
Dr Agarwals Health Care Ltd · AGARWALEYE
—
—
—
—
—
₹23 Cr
₹41 Cr
₹18 Cr
₹21 Cr
₹28 Cr
₹43 Cr
₹38 Cr
₹36 Cr
₹44 Cr
₹50 Cr
₹55 Cr
Gaudium IVF and Women Health Ltd · GAUDIUMIVF⚠ unverified
—
—
—
—
—
—
—
—
₹8 Cr
₹3 Cr
₹6 Cr
₹3 Cr
₹9 Cr
₹4 Cr
₹8 Cr
₹2 Cr
Gujarat Kidney & Super Speciality Ltd · GKSL⚠ unverified
—
—
—
—
—
—
—
—
₹3 Cr
₹3 Cr
₹1 Cr
₹5 Cr
₹3 Cr
₹4 Cr
₹5 Cr
₹5 Cr
KRM Ayurveda Ltd · KRMAYURVED
—
—
—
—
—
—
—
—
—
—
₹5 Cr
₹4 Cr
₹8 Cr
—
₹8 Cr
₹9 Cr
Nephrocare Health Services Ltd · NEPHROPLUS
—
—
—
—
—
—
—
—
—
₹20 Cr
₹25 Cr
₹24 Cr
₹-9 Cr
₹32 Cr
₹30 Cr
₹32 Cr
Park Medi World Ltd · PARKHOSPS
—
—
—
—
—
—
—
—
—
₹46 Cr
₹52 Cr
₹66 Cr
₹79 Cr
₹53 Cr
₹77 Cr
₹89 Cr
Unihealth Hospitals Ltd · UNIHEALTH⚠ unverified
—
—
—
—
₹4 Cr
—
₹6 Cr
—
₹9 Cr
—
₹18 Cr
—
₹29 Cr
—
₹17 Cr
—
Profit growth · reported quarter history
Dr Agarwals Health Care Ltd · AGARWALEYE
—
—
—
—
—
—
—
—
—
22%
4.9%
111%
71%
57%
16%
45%
Gaudium IVF and Women Health Ltd · GAUDIUMIVF⚠ unverified
—
—
—
—
—
—
—
—
—
—
—
—
17%
6.8%
29%
-42%
Gujarat Kidney & Super Speciality Ltd · GKSL⚠ unverified
—
—
—
—
—
—
—
—
—
—
—
—
-2.7%
46%
260%
-1.5%
KRM Ayurveda Ltd · KRMAYURVED
—
—
—
—
—
—
—
—
—
—
—
—
—
—
56%
124%
Nephrocare Health Services Ltd · NEPHROPLUS
—
—
—
—
—
—
—
—
—
—
—
—
—
60%
20%
33%
Park Medi World Ltd · PARKHOSPS
—
—
—
—
—
—
—
—
—
—
—
—
—
15%
48%
35%
Unihealth Hospitals Ltd · UNIHEALTH⚠ unverified
—
—
—
—
—
—
—
—
125%
—
200%
—
222%
—
-5.6%
—
10 · compare level, then change
Return On Capital Employed
KRM Ayurveda Ltd has the highest ROCE among the 7 Hospitals/Medical Services companies compared here, at 35.3%. Gaudium IVF and Women Health Ltd is next at 29.3%. Unihealth Hospitals Ltd has the highest ROCE change at +5.3 percentage points, so level and change sit with different companies. 7 of 7 companies report a comparable reading, the latest through Jun 2026.
What the numbers say: KRM Ayurveda Ltd leads ROCE at 35.3%, 6 percentage points above Gaudium IVF and Women Health Ltd. Unihealth Hospitals Ltd has the strongest latest improvement at +5.3 percentage points. Read the leader beside the density of its reported history: a sparse high return is a candidate; a repeated high return is evidence of durability.
LeaderKRM Ayurveda Ltd · 35.3%
Gap20.5% versus #2 · Gaudium IVF and Women Health Ltd
PersistenceNot enough history
Coverage7/7 companies · 22 observations
Investor read: KRM Ayurveda Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current roce change signal.
ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.
ROCEhighest
1KRM Ayurveda Ltd KRMAYURVED35%
2Gaudium IVF and Women Health Ltd GAUDIUMIVF⚠ unverified29%
ROCE changefastest improvers
5KRM Ayurveda Ltd KRMAYURVED−7.0 pp
Return on capital · company comparison
7/7 level · 7/7 change
Withheld from this chart: Dr Agarwals Health Care Ltd (AGARWALEYE) — its two data sources disagree by up to 31% on reported income across 10 comparable periods, so its derived ratios are withheld; Park Medi World Ltd (PARKHOSPS) — its two data sources disagree by up to 16% on reported income across 5 comparable periods, so its derived ratios are withheld. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
All-company data · latest reported quarter
| Company | ROCE | ROCE change | Reported |
|---|---|---|---|
| Gaudium IVF and Women Health Ltd GAUDIUMIVF⚠ unverified | 20% | −29.2 pp | Jun 2026 |
| Unihealth Hospitals Ltd UNIHEALTH⚠ unverified | 19% | +5.3 pp | Mar 2026 |
| Nephrocare Health Services Ltd NEPHROPLUS | 12% | +3.6 pp | Jun 2026 |
| Gujarat Kidney & Super Speciality Ltd GKSL⚠ unverified | 8.2% | −31.2 pp | Jun 2026 |
Full 16-quarter history · every available company
ROCE · reported quarter history
Gaudium IVF and Women Health Ltd · GAUDIUMIVF⚠ unverified
—
—
—
—
—
—
—
13%
25%
—
49%
—
—
68%
20%
—
Gujarat Kidney & Super Speciality Ltd · GKSL⚠ unverified
—
—
—
—
—
—
—
—
29%
—
39%
44%
41%
55%
8.2%
—
Nephrocare Health Services Ltd · NEPHROPLUS
—
—
—
—
—
—
—
—
—
—
8.3%
11%
16%
19%
12%
—
Unihealth Hospitals Ltd · UNIHEALTH⚠ unverified
—
—
—
—
5.5%
—
16%
—
16%
—
14%
—
19%
—
19%
—
ROCE change · reported quarter history
Gaudium IVF and Women Health Ltd · GAUDIUMIVF⚠ unverified
—
—
—
—
—
—
—
—
—
—
—
—
—
—
−29.2 pp
—
Gujarat Kidney & Super Speciality Ltd · GKSL⚠ unverified
—
—
—
—
—
—
—
—
—
—
—
—
+12.5 pp
—
−31.2 pp
—
Nephrocare Health Services Ltd · NEPHROPLUS
—
—
—
—
—
—
—
—
—
—
—
—
—
—
+3.6 pp
—
Unihealth Hospitals Ltd · UNIHEALTH⚠ unverified
—
—
—
—
—
—
—
—
+10.5 pp
—
−1.4 pp
—
+2.7 pp
—
+5.3 pp
—
11 · compare level, then change
Valuation Against Growth & Quality
Nephrocare Health Services Ltd has the lowest PEG among the 7 Hospitals/Medical Services companies compared here, at 0.04×. KRM Ayurveda Ltd has the lowest P/E at 23.9×, so level and change sit with different companies. 1 of 7 companies report a comparable reading, the latest through Jun 2026.
What the numbers say: Nephrocare Health Services Ltd has the lowest comparable PEG at 0.04×. Only 1 of 7 companies have earnings and growth steady enough for the ratio to mean anything, so no broad “cheapest stock” conclusion is defensible unless the current multiple, own-history position and growth durability agree.
LeaderNephrocare Health Services Ltd · 0.04×
GapNot enough peers
Persistence0/3 recent comparable periods
Coverage1/7 companies · 1 observations
Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.
This conclusion weakens if: The next two comparable reports reverse the current p/e signal.
PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is recomputed consistently as the trailing P/E divided by that growth rate — reported earnings, never an expected-earnings multiple. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing.
PEGlowest PEG
P/Elowest P/E
1KRM Ayurveda Ltd KRMAYURVED23.9
2Gaudium IVF and Women Health Ltd GAUDIUMIVF⚠ unverified38.8
Valuation · company comparison
1/7 level · 7/7 change
All-company data · latest reported quarter
| Company | PEG | P/E | Reported |
|---|---|---|---|
| Nephrocare Health Services Ltd NEPHROPLUS | 0.0 | 48.0 | Jun 2026 |
| Dr Agarwals Health Care Ltd AGARWALEYE | — | 115.9 | Jun 2026 |
| Park Medi World Ltd PARKHOSPS | — | 50.0 | Jun 2026 |
| Gujarat Kidney & Super Speciality Ltd GKSL⚠ unverified | — | 65.7 | Jun 2026 |
| Unihealth Hospitals Ltd UNIHEALTH⚠ unverified | — | 21.6 | Mar 2026 |
| Gaudium IVF and Women Health Ltd GAUDIUMIVF⚠ unverified | — | 36.2 | Jun 2026 |
| KRM Ayurveda Ltd KRMAYURVED | — | 27.2 | Jun 2026 |
Full 16-quarter history · every available company
PEG · reported quarter history
Nephrocare Health Services Ltd · NEPHROPLUS
—
—
—
—
—
—
—
—
—
—
—
—
—
0.0
—
—
P/E · reported quarter history
Dr Agarwals Health Care Ltd · AGARWALEYE
—
—
—
—
—
—
—
—
—
—
—
150.5
202.0
137.8
169.3
115.9
Gaudium IVF and Women Health Ltd · GAUDIUMIVF⚠ unverified
—
—
—
—
—
—
—
—
—
—
—
—
—
—
22.9
36.2
Gujarat Kidney & Super Speciality Ltd · GKSL⚠ unverified
—
—
—
—
—
—
—
—
—
—
—
—
—
62.0
52.8
65.7
KRM Ayurveda Ltd · KRMAYURVED
—
—
—
—
—
—
—
—
—
—
—
—
—
—
0.2
27.2
Nephrocare Health Services Ltd · NEPHROPLUS
—
—
—
—
—
—
—
—
—
—
—
—
—
1.5
1.6
48.0
Park Medi World Ltd · PARKHOSPS
—
—
—
—
—
—
—
—
—
—
—
—
—
27.3
33.0
50.0
Unihealth Hospitals Ltd · UNIHEALTH⚠ unverified
—
—
—
—
46.5
—
20.2
—
22.0
—
14.2
—
9.9
—
21.6
—
12 · before the conclusion, check the blind spots
What can make this comparison misleading?
This Hospitals/Medical Services comparison names 7 specific ways its own evidence can mislead, all listed below. All 7 companies here report on comparable dates, so no rank carries a stale marker. 3 draw at least one figure from a second feed with too little overlap to cross-check. 2 have second-feed figures withheld because the two sources disagree.
Keep these limits visible
- A high growth rate can be a low-base artefact. The page keeps level and change separate for that reason.
- A high ROCE can be temporary or flattered by a small capital base. Read it beside margin, cash conversion and reinvestment.
- The 4-Factor Sector Score ranks research priority, not portfolio action. Management quality, catalysts and risks need equally fresh evidence before capital is deployed.
- An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
- 3 companies draw at least one figure from a second data feed with too little overlapping history to cross-check against the primary source; they are marked unverified wherever those figures appear.
- 2 companies are missing from the second-feed metrics by decision, not by absence: the two sources disagree, so nothing from the second is drawn. Read those rows as narrower evidence, never as a weaker business.
- Thin comparisons: Valuation have fewer than three usable current readings.
13 · evidence and freshness
How was this comparison built?
This comparison is built from the reported filings of 7 Hospitals/Medical Services companies, normalized to a common ₹ scale and a shared quarter axis of up to 16 quarters each. Fundamentals run through Jun 2026 and market data through 2026-08-14. A second data feed fills gaps only after identity and scale reconciliation, and missing observations are never interpolated.
FundamentalsThrough Jun 2026 · up to 16 quarters per company
Market dataThrough 2026-08-14 · weekly price and relative-strength history
Derived metricsGrowth, changes and PEG are calculated only when their inputs are comparable.
Score confidenceMissing and stale evidence reduces confidence and pulls the 0–100 research-priority score toward neutral.
Source standing1 cross-checked · 4 unverified · 2 withheld, of 7 graded companies.
How a second data feed is admitted, and what happens when it disagrees
A second feed is read only after its reported income is matched against the primary source on at least three overlapping periods. Where the two agree the figures fill silently. Where there is too little shared history to compare, the figures are still drawn — they are the only evidence there is — and marked ⚠ unverified everywhere they appear. Where the two are known to disagree, nothing from the second feed is drawn and the affected company is named under the chart it is missing from.
14 · questions investors ask, short speakable answers
Hospitals/Medical Services company comparison FAQs
These 24 answers restate the Hospitals/Medical Services comparison above in question form. Every one is computed from the same 7 companies and the same reported filings as the rankings and charts, current through Jun 2026. Price and relative-strength answers run through 2026-08-14. Nothing here is estimated, and none of it is a recommendation.
Is the Hospitals/Medical Services sector outperforming NIFTY 500?
Hospitals/Medical Services has outperformed NIFTY 500 by 146.2% over 52 weeks and 13% over 13 weeks. 2 of 2 covered companies beat NIFTY on Mansfield relative strength, while 1 of 2 beat the sector itself.
Which Hospitals/Medical Services company is largest by revenue?
Dr Agarwals Health Care Ltd leads with revenue of ₹2,207 crore, based on 5 of 7 comparable companies through Jun 2026.
Which Hospitals/Medical Services company is growing fastest?
Gujarat Kidney & Super Speciality Ltd has the fastest current revenue growth at 100%, across 3 of 7 comparable companies.
Which Hospitals/Medical Services company has the strongest 4-Factor Sector Score?
Unihealth Hospitals Ltd ranks first at 69.3/100 with 55.8% evidence confidence. The score prioritizes research; it is not a buy recommendation.
Which Hospitals/Medical Services company has the lowest comparable PEG?
Nephrocare Health Services Ltd has the lowest comparable PEG at 0.04, among 1 of 7 companies whose earnings and growth are steady enough for the ratio to mean anything.
How much history does this Hospitals/Medical Services comparison include?
The page compares up to 16 reported quarters per company for fundamentals, returns and valuation, ending Jun 2026. Missing observations remain blank rather than being estimated.
How is the 4-Factor Sector Score calculated?
The four visible contributions add directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or stale evidence moves only the affected contribution toward neutral.
Is there a Nifty Hospitals/Medical Services index?
NSE India maintains Nifty indices for several broad sector categories — Nifty Bank, Nifty IT, Nifty Pharma and others — but not for every sub-sector grouping on this site. Whether or not an official Nifty index covers Hospitals/Medical Services, this page builds its own equal-weight basket of 7 listed Hospitals/Medical Services companies — one company, one vote, regardless of market value — so no single large company dominates the reading. Figures are as of Jun 2026.
Which are the best Hospitals/Medical Services stocks in India?
Ranked by this page's four-factor score, Unihealth Hospitals Ltd places first among 7 listed Hospitals/Medical Services companies, followed by Dr Agarwals Health Care Ltd. That is a ranking of published data — earnings, quality, valuation and market behaviour as of Jun 2026 — and not a recommendation; Sector Alpha is not registered with SEBI as an investment adviser.
How many Hospitals/Medical Services stocks are listed in India?
This comparison covers 7 listed Hospitals/Medical Services companies in India, each above the size floor the site applies, with 20 quarters of reported figures per company where the filings exist. The full ranked list is on this page, as of Jun 2026.
Which Hospitals/Medical Services company is the biggest?
Dr Agarwals Health Care Ltd is the largest, with trailing-twelve-month revenue of ₹2,207 crore, ahead of Park Medi World Ltd at ₹1,756 crore. That covers 5 of 7 companies with comparable reporting through Jun 2026.
Which Hospitals/Medical Services company has the best profit margins?
KRM Ayurveda Ltd has the highest operating margin at 37.2%, from 7 of 7 comparable companies. KRM Ayurveda Ltd shows the biggest recent improvement, at +12 percentage points. A high margin matters most when it is holding or rising, not when it is peaking.
Which Hospitals/Medical Services company makes the most profit?
Park Medi World Ltd earns the most, at ₹298 crore of trailing-twelve-month net profit, from 5 of 7 comparable companies. Dr Agarwals Health Care Ltd has the fastest profit growth at 42.3%, though growth off a small or recovering profit base overstates how much has actually changed.
Which Hospitals/Medical Services company earns the highest return on capital?
KRM Ayurveda Ltd leads on return on capital employed at 35.3%, across 7 of 7 companies. Read it beside the length of its reported history: a high return that repeats for years is evidence of a durable business, while a single high reading can be a small capital base or one good year.
Which Hospitals/Medical Services stock is the cheapest?
On PEG — where a LOWER number is cheaper — Nephrocare Health Services Ltd screens cheapest at 0.04×. Only 1 of 7 companies have earnings and growth steady enough for the ratio to mean anything, so this is not a sector-wide "cheapest stock" verdict. Cheap on a multiple is a reason to investigate, never a reason to buy on its own.
Is the Hospitals/Medical Services sector beating the market?
Hospitals/Medical Services has outperformed NIFTY 500 by 146.2% over the last 52 weeks and 13% over 13 weeks, measured on an equal-weight index of its current members. Inside the sector, 2 of 2 covered companies are beating the market on their own. Sector strength does not transfer evenly to every stock in it.
Which Hospitals/Medical Services stock has the strongest price momentum?
Unihealth Hospitals Ltd has the strongest relative strength against NIFTY 500. Relative strength answers last, after growth, quality and valuation: price can move well before the fundamentals confirm it, and sometimes without them confirming at all.
Which Hospitals/Medical Services company scores highest for research priority?
Unihealth Hospitals Ltd scores 69.3 out of 100 with 55.8% evidence confidence, from 19 points on growth and earnings, 19.8 on capital efficiency, 10.5 on valuation and 20 on relative strength. This ranks what deserves work next. It is not a buy recommendation, and management quality, catalysts and risk still need separate research.
How many Hospitals/Medical Services companies does this comparison cover, and over what period?
It compares 7 listed companies over up to 16 reported quarters of fundamentals, ending Jun 2026, plus weekly price and relative-strength history. Membership is the full sector list — nothing is dropped for having thin data.
What is the total market cap of the Hospitals/Medical Services sector?
The 7 Hospitals/Medical Services companies on this page carry ₹38,864 crore of combined market value. Dr Agarwals Health Care Ltd is the largest at ₹16,057 crore, about 41% of the sector's total on its own. Market value moves with price, so this reading is dated 2026-08-18.
What is the Hospitals/Medical Services sector's P/E ratio?
The median price-to-earnings ratio across the 7 Hospitals/Medical Services companies on this page is 43.8×, measured on the 7 that report a comparable figure. A sector-level history for this multiple is not held here, so this is a cross-section of today, not a comparison with the sector’s own past. Figures are as of 2026-08-18.
How is the Hospitals/Medical Services sector performing?
2 of the 2 covered Hospitals/Medical Services companies are beating NIFTY 500 on Mansfield relative strength. The sector itself is 146.2% ahead of NIFTY 500 over 52 weeks on an equal-weight index of its current members. Readings are as of 2026-08-18.
Why are some values on this page blank?
A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing observations are never interpolated, carried forward, or replaced with a similar-looking accounting line, and a company with missing evidence has its research score pulled toward neutral rather than being scored as bad.
Is this investment advice?
No. Every figure here is a deterministic calculation from reported company filings and market data, published for research. It contains no recommendation to buy or sell any security, does not account for your circumstances, and is not a substitute for advice from a licensed adviser.